Expression and clinical significance of Ezrin in non-small-cell lung cancer

Clinical Lung Cancer

Volumn 13, Issue 3, 2012, Pages 196-204

  Zhang, Xiao Qin ^a,b   Chen, Guo Ping ^a   Wu, Tao ^a   Yan, Jian Ping ^b   Zhou, Jian Ying ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Disease free survival; Metastasis; Overall survival; Prognosis

Indexed keywords

EZRIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CYTOSKELETAL PROTEINS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859873801     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.04.002     Document Type: Article

References (40)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics. CA Cancer J Clin 2004; 54:8-29.
2. World Health Organization. Histological Typing of Lung and Pleural Tumors. International Histological Classification of Tumors. 3rd ed. Geneva: World Health Organization, 1999.
3. Blake DC Jr, Mikse OR, Freeman WM, et al. FOXO3a elicits a pro-apoptotic transcription program and cellular response to human lung carcinogen nicotine-derived nitrosaminoketone (NNK). Lung Cancer 2010; 67:37-47.
4. Soria JC, Kim ES, Fayette J, et al. Chemoprevention of lung cancer. Lancet Oncol 2003; 4:659-69. (Pubitemid 37407433)
5. Ling X, Yang J, Tan D, et al. Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer 2005; 49:353-61. (Pubitemid 41139148)
6. Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995; 13:1221-30.
7. Yoshida BA, Sokoloff MM, Welch DR, et al. Metastasis-suppressor genes: a review and perspective. J Natl Cancer Inst 2000; 92:1717-30.
8. Xu A, Hao J, Zhang Z, et al. 14-kDa phosphohistidine phosphatase and its role in human lung cancer cell migration and invasion. Lung Cancer 2010; 67:48-56.
9. Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 2002; 3:586-99.
10. Gautreau A, Poullet P, Louvard D, et al. Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1999; 96:7300-5. (Pubitemid 29299656)
11. Martin TA, Harrison G, Mansel RE, et al. The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 2003; 46:165-86. (Pubitemid 36452345)
12. Hunter KW. Ezrin, a key component in tumor metastasis. Trends Mol Med 2004; 10:201-4. (Pubitemid 38581790)
13. Weng WH, Ahlén J, Aström K, et al. Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res 2005; 11:6198-204. (Pubitemid 41262948)
14. Zeng H, Xu L, Xiao D, et al. Altered expression of ezrin in esophageal squamous cell carcinoma. J Histochem Cytochem 2006; 54:889-96. (Pubitemid 44106866)
15. Torer N, Kayaselcuk F, Nursal TZ, et al. Adhesion molecules as prognostic markers in pancreatic adenocarcinoma. J Surg Oncol 2007; 96:419-23. (Pubitemid 47519448)
16. Bal N, Yildirim S, Nursal TZ, et al. Association of ezrin expression in intestinal and diffuse gastric carcinoma with clinicopathological parameters and tumor type. World J Gastroenterol 2007; 13:3726-9. (Pubitemid 47202171)
17. Köbel M, Langhammer T, Hüttelmaier S, et al. Ezrin expression is related to poor prognosis in FIGO stage I endometrial carcinomas. Mod Pathol 2006; 19:581-7.
18. Köbel M, Gradhand E, Zeng K, et al. Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma. Int J Gynecol Pathol 2006; 25:121-30. (Pubitemid 44620173)
19. Elliott BE, Meens JA, SenGupta SK, et al. The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res 2005; 7:365-73.
20. Frey A, Soubani AO, Adam AK, et al. Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in stage I, improved survival. Histopathology 2009; 54:590-7.
21. Tsurutani J, Steinberg SM, Ballas M, et al. Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. Lung Cancer 2007; 55:115-21. (Pubitemid 46038882)
22. Khanna C, Khan J, Nguyen P, et al. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 2001; 61:3750-9. (Pubitemid 32694989)
23. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004; 10:182-6. (Pubitemid 38524889)
24. Yu Y, Khan J, Khanna C, et al. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 2004; 10:175-81. (Pubitemid 38524888)
25. Akisawa N, Nishimori I, Iwamura T, et al. High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem Biophys Res Commun 1999; 258:395-400. (Pubitemid 29287062)
26. Elliott BE, Meens JA, SenGupta SK, et al. The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res 2005; 7:R365-73.
27. McClatchey AI. Merlin and ERM proteins: unappreciated roles in cancer development? Nat Rev Cancer 2003; 3:877-83. (Pubitemid 37376984)
28. Moilanen J, Lassus H, Leminen A, et al. Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients. Gynecol Oncol 2003; 90:273-81. (Pubitemid 36952014)
29. Karmakar S, Das C. Modulation of ezrin and E-cadherin expression by IL-1 beta and TGF-beta1 in human trophoblasts. J Reprod Immunol 2004; 64:9-29. (Pubitemid 39642850)
30. Krishnan K, Bruce B, Hewitt S, et al. Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clin Exp Metastasis 2006; 23:227-36. (Pubitemid 44673812)
31. Townson JL, Naumov GN, Chambers AF. The role of apoptosis in tumor progression and metastasis. Curr Mol Med 2003; 3:631-42. (Pubitemid 37236405)
32. Lozupone F, Lugini L, Matarrese P, et al. Identification and relevance of the CD95-binding domain in the N-terminal region of ezrin. J Biol Chem 2004; 279:9199-207. (Pubitemid 38295983)
33. Luciani F, Matarrese P, Giammarioli AM, et al. CD95/phosphorylated ezrin association underliesHIV-1GP120/IL-2-induced susceptibility toCD95(APO-1/Fas)- mediatedapoptosis of human resting CD4(+) T lymphocytes. Cell Death Differ 2004; 11:574-82. (Pubitemid 38660142)
34. Sarrió D, Rodríguez-Pinilla SM, Dotor A, et al. Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas. Breast Cancer Res Treat 2006; 98:71-9. (Pubitemid 44050782)
35. Yeh TS, Tseng JH, Liu NJ, et al. Significance of cellular distribution of ezrin in pancreatic cystic neoplasms and ductal adenocarcinoma. Arch Surg 2005; 140:1184-90.
36. Cui Y, Li T, Zhang D, et al. Expression of Ezrin and phosphorylated Ezrin (pEzrin) in pancreatic ductal adenocarcinoma. Cancer Invest 2010; 28:242-7.
37. Hiscox S, Jiang WG. Ezrin regulates cell-cell and cell-matrix adhesion, a possible role with E-cadherin/beta-catenin. J Cell Sci 1999; 112:3081-90. (Pubitemid 29465726)
38. Bretscher A. Regulation of cortical structure by the ezrin-radixin-moesin protein family. Curr Opin Cell Biol 1999; 11:109-16. (Pubitemid 29084138)
39. Louvet-Vallée S. ERM proteins: from cellular architecture to cell signaling. Biol Cell 2000; 92:305-16.
40. Meng Y, Kang S, So J, et al. Translocation of Fas by LPA prevents ovarian cancer cells from anti-Fas-induced apoptosis. Gynecol Oncol 2005; 96:462-9. (Pubitemid 40127149)